Phytotherapie bei chronisch entzündlichen Darmerkrankungen*

• Literatur

• 1 Bauer N, Kairey L, Schlee C. et al. Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002. Scand J Gastroenterol 2022; 57: 1209-1215
• 2 DGVS. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1). 2023 https://register.awmf.org/assets/guidelines/021-009l_S3_Colitis-ulcerosa_2023-03.pdf
• 3 DGVS. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“. 2021 https://register.awmf.org/assets/guidelines/021-004l_S3_Morbus_Crohn_Diagnostik_Therapie_2022-04.pdf
• 4 Burge K, Gunasekaran A, Eckert J, Chaaban H. Curcumin and intestinal inflammatory diseases: molecular mechanisms of protection. Int J Mol Sci 2019; 20: 1912
• 5 Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Curcumin and its potential impact on microbiota. Nutrients 2021; 13: 2004
• 6 Karner M, Kocjan A, Stein J. et al. First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014; 109: 1041-1051
• 7 Stremmel W, Vural H, Evliyaoglu O, Weiskirchen R. Delayed-release phosphatidylcholine is effective for treatment of ulcerative colitis: A meta-analysis. Dig Dis 2021; 39: 508-515
• 8 Schmidgall J, Schnetz E, Hensel A. Evidence for bioadhesive effects of polysaccharides and polysaccharide-containing herbs in an ex vivo bioadhesion assay on buccal membranes. Planta Med 2000; 66: 48-53
• 9 Huber R, Ditfurth AV, Amann F. et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007; 41: 834-838
• 10 Weber L, Kuck K, Jürgenliemk G. et al. Anti-inflammatory and barrier-stabilising effects of myrrh, coffee charcoal and chamomile flower extract in a co-culture cell model of the intestinal mucosa. Biomolecules 2020; 10: 1033
• 11 Langhorst J, Varnhagen I, Schneider SB. et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013; 38: 490-500
• 12 Sandborn WJ, Targan SR, Byers VS. et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108: 90-98
• 13 Michelsen KS, Wong MH, Ko B. et al. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bowel Dis 2013; 19: 151-164
• 14 Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease: a double-blind placebo-controlled study. Phytomedicine 2007; 14: 87-95
• 15 Holtmeier W, Zeuzem S, Preiss J. et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011; 17: 573-582
• 16 Schmiech M. Untersuchung von Harzen des Weihrauchbaums (Boswellia spp.) hinsichtlich chemischer Zusammensetzung, zytokinregulatorischer Eigenschaften und Wirkung auf Mammakarzinomzellen [Dissertation]. Universität Ulm 2021;
• 17 Devi S, Zimmermann-Klemd AM, Fiebich BL. et al. Immunosuppressive activity of non-psychoactive Cannabis sativa L. extract on the function of human T lymphocytes. Int Immunopharmacol 2022; 103: 108448
• 18 Naftali T, Bar-Lev Schleider L, Almog S. et al. Oral CBD-rich Cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomised controlled trial. J Crohns Colitis 2021; 15: 1799-1806